



AC

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 35/78		A1	(11) International Publication Number: WO 00/02570 (43) International Publication Date: 20 January 2000 (20.01.00)
<p>(21) International Application Number: PCT/EP99/02358</p> <p>(22) International Filing Date: 7 April 1999 (07.04.99)</p> <p>(30) Priority Data: MI98A001542 7 July 1998 (07.07.98) IT</p> <p>(71) Applicant (for all designated States except US): INDENA S.P.A. [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT).</p> <p>(72) Inventors; and</p> <p>(73) Inventors/Applicants (for US only): BOMBARDELLI, Ezio [IT/IT]; Via Val di Sole, 22, I-20141 Milano (IT). GABETTA, Bruno [IT/IT]; Viale Ortles, 12, I-20139 Milano (IT).</p> <p>(74) Agent: MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: EXTRACTS OF ZANTHOXYLUM BUNGEANUM, PHARMACEUTICAL AND COSMETIC FORMULATIONS CONTAINING THEM</p> <p>(57) Abstract</p> <p>The extracts of Zanthoxylum bungeanum obtainable by extraction of the pericarp with supercritical CO₂ have improved pharmacological characteristics.</p> <p style="text-align: right;"><i>Best Available Copy</i></p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

1

EXTRACTS OF ZANTHOXYLUM BUNGEANUM, PHARMACEUTICAL AND
COSMETIC FORMULATIONS CONTAINING THEM

The present invention relates to a novel extract obtained by extraction of the pericarp of *Zanthoxylum bungeanum* with carbon dioxide and to the pharmaceutical and cosmetic formulations containing it. This extract
5 has antiinflammatory and analgesic activities and can be used for the treatment of itching.

Pericarp of *Zanthoxylum bungeanum* is commonly used in China as spices for seasoning food. Moreover, in Chinese and Indian folk medicine, this part of the plant
10 is used as local anaesthetic and for the treatment of dysentery. The essential oil, which contains a series of monoterpenes such as 1,8-cimol, linalool, 4-terpinol, caryophyllene, limonene and the like, is reported as a strong repellent against insects.

15 Recently, EP 568001 disclosed the antiviral activity of the skin of this fruit.

In US 5,137,912 chelcrysyrhine, extracted from the root bark of *Zanthoxylum simulans* (synonym of *bungeanum*), was disclosed to be active in the prevention
20 of thrombosis. According to JP 01294657, the extraction of the pericarp with organic solvents provides an extract containing isobutylamides exerting local anaesthetic effect already 30 seconds after the application on the tongue and lasting up to 20-80
25 minutes.

It has now surprisingly been found that the extract of the pericarp of *Zanthoxylum bungeanum*, prepared by extraction with carbon dioxide in supercritical conditions, has a remarkable analgesic activity without

exerting the local anaesthetic activity characteristic of the extracts obtained by means of solvents. The product of the present invention is prepared extracting the pericarp of *Zanthoxylum bungeanum*, finely ground or 5 transformed into pellets, with carbon dioxide under pressure conditions ranging from 150 to 300 bars, preferably under 180-230 bars, at temperatures ranging from 35 to 55°C, preferably at 35-40°C.

10 The resulting extract can either be used as it is, after removing the extraction water, or further be purified by partitioning it with immiscible solvents such as aliphatic alcohols and aliphatic hydrocarbons, preferably n-hexane or petroleum ether.

15 The resulting extracts proved to exert a marked analgesic activity when applied percutaneously to humans; therefore they are valuable for use both in the pharmaceutical and cosmetic fields.

20 In the pharmaceutical field, they are useful for alleviating pain in diabetic microangiopathy, in hemorrhoidal pain, in burns and in any form of local pain. A further application of the extracts of the invention is the treatment of itching.

25 In the cosmetic field, the extracts according to the invention are useful in depilatory creams, after-sun formulations, shaving lotions and creams, and in all the skin treatments requiring local analgesic and anti-itching actions.

30 The anti-itching activity of the extracts of the invention was evaluated through electrophysiological measurements using the experimental model of the rat ischiatic nerve-musculus extensor digitorum longus (EDL) preparation in vitro.

Adult Sprague-Dawley rats killed by an intracardial Penthotal overdose were used. The EDL muscle with a long tract of ischiatic nerve was dissected and placed in a container for electrophysiology with a Ringer solution which was substituted every 10 minutes. The tested extracts, preferably added with a surfactant, were dispersed in different concentrations, thereby coming into contact with nerve fibers, neuromuscular junctions and muscle. For the electrophysiological tests, an intracellular microelectrode filled with 3M KCl was placed in muscle cells for recording the electrical phenomena (miniature endplate potentials, endplate potentials, membrane potentials of the muscle cell) both spontaneous and induced by stimulation of the nerve. For this purpose, the nerve was linked to a stimulator and optionally stimulated once a second. The electric events in the muscle cells were detected by the microelectrode linked to a signal amplifier and made visible through a digital oscilloscope.

The extracts of the invention, when tested at concentrations ranging from 0.0005 to 0.002%, exert a strong, transitory activating action on the neuromuscular synaptic transmission, evidenced by the increase in the frequency of the miniature endplate potentials and by the appearance of spontaneous endplate potentials. Conversely, the extracts obtained with solvents, having local anaesthetic activity, reduce and inhibit the transmission of the nervous impulse.

The analgesic activity of the tested extracts was evaluated in 10 healthy volunteers through an evaluation study of the skin thermal sensitivity.

A progressively heated thermal probe was placed on the scapular area of the subject 30 minutes after treatment with the tested product or with the corresponding placebo. The value of the temperature considered painful by the subject was measured. 0.5 ml of an emulsion prepared according to Example VII, containing 0.5% of an extract of *Zanthoxylum bungeanum* prepared according to Example I, were administered. The results reported in the following show the analgesic activity of the tested extract.

Treatment	T ₀	T _{30min}
Placebo	45.7±1.0	45.3±0.4
Extract	46.0±0.8	47.2±0.4

The extracts of the invention can be formulated in the form of creams, lotions, foams, gels, for the administration on the skin or mucosas, soft-gelatin capsules, hard-gelatin capsules, tablets or suppositories; preferably the extract of the invention is formulated in creams or foams for the cutaneous treatment or in soft-gelatin capsules, chewable tablets or suppositories for the systemic route.

The extract dosages in the formulations range between 5 and 100 mg per dose in the formulations for the systemic use, whereas they vary from 0.05 to 1% in the topical formulations.

The examples reported hereinbelow further illustrate the invention without limiting it.

EXAMPLE I - Preparation of a *Zanthoxylum bungeanum* lipophilic extract

10 Kg of pericarp of *Zanthoxylum bungeanum* are extracted according to the procedure reported below, in a 25 L extraction plant for supercritical gas, equipped

with two separators as condensers for fractioning the extract.

10 Kg of pericarp mechanically dried after harvesting at a temperature not higher than 60°C, were 5 extruded into cubes and extracted with CO₂ in supercritical conditions under the following experimental conditions:

- temperature: 35°C in the extractor, 30°C in the first separator and 20°C in the second separator;
- 10 - pressure: 180 bars in the extractor, 100 bars in the first separator and 50 bars in the second separator.

The CO₂ flow was 10 L per minute for 45 minutes. The extract was concentrated in the second separator, whereas most water present in the vegetable matrix was 15 concentrated in the first separator. After drying the extract in the second separator under vacuum at a temperature not above 40°C, 1.5 Kg of pasty extract were obtained, which was slightly coloured in yellow, intensely scented and had a content in isobutylamides of 20 about 25% by weight. HPLC analysis was carried out on a Hibar RT LiChrospher 100RP-18 column with the elution profile (1mL/min) reported in the table. The injected amount was 5 µL of a solution of concentration 2 mg/mL. The chromatogram is reported in the figure.

25 **TABLE**

TIME (min)	WATER (%)	ACETONITRILE (%)	NUMBER OF THE GRADIENT CURVE
0	60	40	-
20	60	40	6
30	10	90	6
35	60	40	6
40	60	40	6

EXAMPLE II - Preparation of a Zanthoxylum bungeanum lipophilic extract

10 Kg of pericarp mechanically dried after harvesting at a temperature not higher than 60°C, were 5 extruded into cubes and extracted with CO₂ in supercritical conditions under the following experimental conditions:

- temperature: 40°C in the extractor, 30°C in the first separator and 20°C in the second separator;
10 - pressure: 205 bars in the extractor, 100 bars in the first separator and 50 bars in the second separator. The CO₂ flow was 10 L per minute for 45 minutes. The extract was concentrated in the second separator, whereas most water present in the vegetable matrix was 15 concentrated in the first separator. After drying the extract in the second separator under vacuum at a temperature not above 40°C, 1.5 Kg of pasty extract were obtained, which was slightly coloured in yellow/green and had the same chemical-physical characteristics as 20 the extract of example I, and an about 20% content in isobutylamides.

EXAMPLE III - Preparation of a Zanthoxylum bungeanum lipophilic extract

10 Kg of pericarp mechanically dried after 25 harvesting at a temperature not higher than 60°C, were extruded into cubes and extracted with CO₂ in supercritical conditions under the following experimental conditions: temperature in the extractor 40°C and pressure 230 bars. The ratio of CO₂ used for 30 the extraction of the drug to be extracted was 27-45 Kg per Kg of drug. The extract was concentrated in a separator under 50 bars at 20°C. After drying under

vacuum at a temperature not higher than 40°C, 1.3 Kg of pasty extract were obtained, which was slightly coloured in yellow/green, and had the same chemical-physical characteristics as the extract of example I.

5 **EXAMPLE IV - Preparation of a purified lipophilic extract of Zanthoxylum bungeanum**

0.5 Kg of lipophilic extract of pericarp of Zanthoxylum bungeanum prepared according to Example I were dissolved in 2.5 L of 95% aqueous methanol and 10 extracted three times with 0.5 L each of n-hexane. The hexane phase was counterwashed with methanol using as marker the isobutylamides which should remain in the methanol phase. The inactive hexane phase was removed, whereas the methanol ones were combined, diluted with 15 0.6 L of water and re-extracted twice with 0.6 L of n-hexane. The combined hexane phases were decolourized with 0.3% charcoal, dried over Na_2SO_4 and concentrated to an oil at a temperature not higher than 40°C under 20 vacuum, to obtain 0.22 Kg of an oily extract with honey-like consistence, having a content in isobutylamides of about 50%.

EXAMPLE V - Zanthoxylum bungeanum alcoholic solution

100 ml contain:

Zanthoxylum Bungeanum

25 20% solution in Oleyl Alcohol 0.50 g

Cyclomethicone 20.00 g

Alcohol 100.0 ml

EXAMPLE VI - Zanthoxylum bungeanum analcoholic solution

100 ml contain:

30 Zanthoxylum Bungeanum

20% solution in Oleyl Alcohol 0.50 g

PPG-26 Buteth 26 and

PEG-40 Hydrogenated Castor Oil	5.00 g
Methyl Chloroisothiazolinone and	
Methyl Isothiazolinone	0.10 g
Purified water	q.s. to 100.0 ml

5 **EXAMPLE VII - Zanthoxylum bungeanum emulsion**

100 g contain:

Zanthoxylum Bungeanum	
20% solution in Oleyl Alcohol	0.50 g
Isohexadecane	5.00 g
10 Glycerin	4.00 g
C ₁₂₋₁₅ Alkyl Benzoate	2.00 g
Cyclomethicone	2.00 g
PEG-20 Glyceryl Stearate and	
Glyceryl Stearate	2.00 g
15 Lanolin wax	1.00 g
Acrylates/C ₁₀₋₃₀ Alkyl Acrylate	
Crosspolymer	0.50 g
Cetyl Alcohol	0.50 g
Imidazolidinyl urea	0.30 g
20 Phenoxyethanol	0.50 g
Methyl paraben	0.20 g
Tocopherol	0.10 g
Disodium EDTA	0.10 g
Water	q.s. to 100.0 g

25 **EXAMPLE VIII - Zanthoxylum bungeanum fluid emulsion**

100 g contain:

Zanthoxylum Bungeanum	
20% solution in Oleyl Alcohol	0.50 g
PEG-20 Glyceryl Stearate and	
30 Glyceryl Stearate	10.00 g
C ₁₀₋₁₈ Triglycerides	10.00 g
Glycerin	5.00 g


	Wheat Germ Oil	2.00 g
	Dimethicone	2.00 g
	PPG-25 Laureth-25	2.00 g
	Cetyl Alcohol	1.00 g
5	Hydroxylated Lanolin	0.50 g
	Imidazolidinyl urea	0.30 g
	Hectorite (e) Hydroxyethyl	0.50 g
	Phenoxyethanol and Methylparaben and	
	Ethylparaben and Propylparaben and	
10	Butylparaben	0.50 g
	Tocopherol	0.10 g
	Water	q.s. to 100.0 g

CLAIMS

1. Extracts of *Zanthoxylum bungeanum* obtainable by extraction of the pericarp with supercritical CO_2 .
- 5 2. Extracts as claimed in claim 1 obtainable by extraction with CO_2 at temperatures ranging from 35 to 55°C and under pressures ranging from 150 to 300 bars.
3. Extracts as claimed in claims 1 and 2 having a content in isobutylamides ranging from 20% to 50% by 10 weight.
4. Pharmaceutical compositions containing as active ingredient an extract of claims 1 to 3 in admixture with suitable excipients.
5. Cosmetic compositions containing as active 15 ingredient an extract of claims 1 to 3 in admixture with suitable excipients.

1 / 1

FIG. 1



INTERNATIONAL SEARCH REPORT

In. .ational Application No
PCT/EP 99/02358A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K35/78

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 014, no. 077 (C-0688), 14 February 1990 & JP 01 294657 A (WAKUNAGA PHARMACEUT CO LTD), 28 November 1989 see abstract ---	1-3
X	KENJI MIZUTANI ET AL.: "AMIDES FROM HUAJIAO, PERICARPS OF ZANTHOXYLUM BUNGEANUM MAXIM." CHEMICAL AND PHARMACEUTICAL BULLETIN., vol. 36, no. 7, 1988, pages 2362-2365, XP002108095 TOKYO JP see the whole document --- -/-	1-3

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority, claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

- *&* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

2 July 1999

15/07/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Rempp, G

INTERNATIONAL SEARCH REPORT

b International Application No
PCT/EP 99/02358

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	XIN-LI HUANG ET AL.: "EFFECTS OF EXTRACTS OF ZANTHOXYLUM FRUIT AND THEIR CONSTITUENTS ON SPONTANEOUS BEATING RATE OF MYOCARDIAL CELL SHEETS IN CULTURE." PHYTOTHERAPY RESEARCH, vol. 7, no. 1, January 1993 - February 1993, pages 41-48, XP002108096 see the whole document -----	1-3

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.